SFY 2017 - 2018 MC MLR Report Summary
HIV SNP line of business
- Report also available in Portable Document Format (PDF)
| SFY 2017 - 2018 MC MLR Report Summary | |||||||
|---|---|---|---|---|---|---|---|
| HIV SNP line of business | |||||||
| Plan | MLR AFTER Credibility Adjustment |
Medical Expense (Total Numerator) |
Premium (Total Denominator) |
Remittance | Credible | MMs | |
| Amida Care Inc. | 92.93% | $349,460,998 | $385,925,941 | $0 | Partially Credible | 75,699 | |
| MetroPlus Health Plan, Inc | 98.30% | $206,878,149 | $216,744,066 | $0 | Partially Credible | 50,877 | |
| VNS (d/b/a VNSNY Choice) and Subsidiary | 83.43% | $168,699,200 | $210,407,965 | $5,407,485 | Partially Credible | 40,400 | |
| Total | $725,038,347 | $813,077,972 | $5,407,485 | 166,976 | |||
NOTES:
Please note that the Remittance is for this line of business for one year ONLY based on a MLR Target of 86%.
No remittance for plan if Non-Credible
